121 related articles for article (PubMed ID: 38037845)
1. Successful Prediction of Human Hepatic Concentrations of Transported Drugs Using the Proteomics-Informed Relative Expression Factor Approach.
Yin M; Balhara A; Marie S; Tournier N; Gáborik Z; Unadkat JD
Clin Pharmacol Ther; 2024 Mar; 115(3):595-605. PubMed ID: 38037845
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Hepatobiliary Clearances and Hepatic Concentrations of Transported Drugs in Humans Using Rosuvastatin as a Model Drug.
Storelli F; Li CY; Sachar M; Kumar V; Heyward S; Sáfár Z; Kis E; Unadkat JD
Clin Pharmacol Ther; 2022 Sep; 112(3):593-604. PubMed ID: 35152400
[TBL] [Abstract][Full Text] [Related]
3. Successful Prediction of Positron Emission Tomography-Imaged Metformin Hepatic Uptake Clearance in Humans Using the Quantitative Proteomics-Informed Relative Expression Factor Approach.
Sachar M; Kumar V; Gormsen LC; Munk OL; Unadkat JD
Drug Metab Dispos; 2020 Nov; 48(11):1210-1216. PubMed ID: 32843330
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF Approach.
Kumar V; Yin M; Ishida K; Salphati L; Hop CECA; Rowbottom C; Xiao G; Lai Y; Mathias A; Chu X; Humphreys WG; Liao M; Nerada Z; Szilvásy N; Heyward S; Unadkat JD
Drug Metab Dispos; 2021 Feb; 49(2):159-168. PubMed ID: 33051248
[TBL] [Abstract][Full Text] [Related]
5. Comparative Hepatic and Intestinal Efflux Transport of Statins.
Deng F; Tuomi SK; Neuvonen M; Hirvensalo P; Kulju S; Wenzel C; Oswald S; Filppula AM; Niemi M
Drug Metab Dispos; 2021 Sep; 49(9):750-759. PubMed ID: 34162690
[TBL] [Abstract][Full Text] [Related]
6. Successful Prediction of In Vivo Hepatobiliary Clearances and Hepatic Concentrations of Rosuvastatin Using Sandwich-Cultured Rat Hepatocytes, Transporter-Expressing Cell Lines, and Quantitative Proteomics.
Ishida K; Ullah M; Tóth B; Juhasz V; Unadkat JD
Drug Metab Dispos; 2018 Jan; 46(1):66-74. PubMed ID: 29084782
[TBL] [Abstract][Full Text] [Related]
7. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.
Kunze A; Huwyler J; Camenisch G; Poller B
Drug Metab Dispos; 2014 Sep; 42(9):1514-21. PubMed ID: 24989890
[TBL] [Abstract][Full Text] [Related]
8. Successful Prediction of Fetal Exposure to Dual BCRP/P-gp Drug Substrates Using the Efflux Ratio-Relative Expression Factor Approach and PBPK M&S.
Balhara A; Yin M; Unadkat JD
Clin Pharmacol Ther; 2024 May; 115(5):1044-1053. PubMed ID: 38124355
[TBL] [Abstract][Full Text] [Related]
9. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
10. Successful Prediction of Human Steady-State Unbound Brain-to-Plasma Concentration Ratio of P-gp Substrates Using the Proteomics-Informed Relative Expression Factor Approach.
Storelli F; Anoshchenko O; Unadkat JD
Clin Pharmacol Ther; 2021 Aug; 110(2):432-442. PubMed ID: 33675056
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic Static Model based Prediction of Transporter Substrate Drug-Drug Interactions Utilizing Atorvastatin and Rifampicin.
Mitra P; Kasliwala R; Iboki L; Madari S; Williams Z; Takahashi R; Taub ME
Pharm Res; 2023 Dec; 40(12):3025-3042. PubMed ID: 37821766
[TBL] [Abstract][Full Text] [Related]
13. Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters.
Han YH; Busler D; Hong Y; Tian Y; Chen C; Rodrigues AD
Drug Metab Dispos; 2010 Jul; 38(7):1072-82. PubMed ID: 20360302
[TBL] [Abstract][Full Text] [Related]
14. A Comparison of Total and Plasma Membrane Abundance of Transporters in Suspended, Plated, Sandwich-Cultured Human Hepatocytes Versus Human Liver Tissue Using Quantitative Targeted Proteomics and Cell Surface Biotinylation.
Kumar V; Salphati L; Hop CECA; Xiao G; Lai Y; Mathias A; Chu X; Humphreys WG; Liao M; Heyward S; Unadkat JD
Drug Metab Dispos; 2019 Apr; 47(4):350-357. PubMed ID: 30622164
[TBL] [Abstract][Full Text] [Related]
15. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
16. Protein Abundance of Drug Transporters in Human Hepatitis C Livers.
Droździk M; Lapczuk-Romanska J; Wenzel C; Skalski Ł; Szeląg-Pieniek S; Post M; Syczewska M; Kurzawski M; Oswald S
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887291
[TBL] [Abstract][Full Text] [Related]
17. Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3.
Gozalpour E; Greupink R; Wortelboer HM; Bilos A; Schreurs M; Russel FG; Koenderink JB
Mol Pharm; 2014 Jun; 11(6):1844-55. PubMed ID: 24754247
[TBL] [Abstract][Full Text] [Related]
18. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
Yamashiro W; Maeda K; Hirouchi M; Adachi Y; Hu Z; Sugiyama Y
Drug Metab Dispos; 2006 Jul; 34(7):1247-54. PubMed ID: 16624871
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions.
Zhang Q; Zhang Y; Boer J; Shi JG; Hu P; Diamond S; Yeleswaram S
Drug Metab Dispos; 2017 Jun; 45(6):612-623. PubMed ID: 28283500
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
